Risk of relapse phenotype recurrence in multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 11, 2014, Pages 1511-1522

  Kalincik, Tomas ^a,b   Buzzard, Katherine ^a   Jokubaitis, Vilija ^b   Trojano, Maria ^c   Duquette, Pierre ^d   Izquierdo, Guillermo ^e   Girard, Marc ^d   Lugaresi, Alessandra ^f   Grammond, Pierre ^g   Grand'Maison, Francois ^h   Oreja Guevara, Celia ⁱ   Boz, Cavit ^j   Hupperts, Raymond ^k   Petersen, Thor ^l   Giuliani, Giorgio ^m   Iuliano, Gerardo ⁿ   Lechner Scott, Jeannette ^o   Barnett, Michael ^q   Bergamaschi, Roberto ^q   Van Pesch, Vincent ^q   Amato, Maria Pia ^q   Van Munster, Erik ^q   Fernandez Bolanos, Ricardo ^q   Verheul, Freek ^q   Fiol, Marcela ^q   Cristiano, Edgardo ^q   Slee, Mark ^q   Rio, Maria Edite ^q   Spitaleri, Daniele ^p   Alroughani, Raed ^q   Gray, Orla ^q   Saladino, Maria Laura ^q   Flechter, Sholmo ^q   Herbert, Joseph ^q   Cabrera Gomez, Jose Antonio ^q   Vella, Norbert ^q   Paine, Mark ^q   Shaw, Cameron ^q   Moore, Fraser ^q   Vucic, Steve ^q   Savino, Aldo ^q   Singhal, Bhim ^q   Petkovska Boskova, Tatjana ^q   Parratt, John ^q   Sirbu, Carmen Adella ^q   Rozsa, Csilla ^q   Liew, Danny ^q   Butzkueven, Helmut ^a,b   more..

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF BARI   (Italy)

^d NOTRE DAME HOSPITAL   (Canada)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f UNIVERSITY OF CHIETI   (Italy)

^g Hotel Dieu de Levis Hospital   (Canada)

^h HÔPITAL CHARLES LEMOYNE   (Canada)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^k Zuyderland Medical Centre   (Netherlands)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m Ospedale di Macerata   (Italy)

ⁿ Ospedali Riuniti di Salerno   (Italy)

^o JOHN HUNTER HOSPITAL   (Australia)

^p S G MOSCATI HOSPITAL   (Italy)

^q AORN San Giuseppe Moscati ^*

more..

Author keywords

MSBase; Multiple sclerosis; phenotype; presentation of neurological diseases; prognosis

Indexed keywords

ADULT; ARTICLE; BRAIN STEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PHENOTYPE; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; ADOLESCENT; AGE; BLADDER DISEASE; CEREBELLUM DISEASE; CHILD; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE REGISTRY; DISEASE SEVERITY; INFANT; MIDDLE AGED; NEUROGENIC BOWEL; NEWBORN; PROGNOSIS; PYRAMIDAL SIGN; RECURRENCE RISK; RISK ASSESSMENT; SENSORY DYSFUNCTION; SEX DIFFERENCE; VISUAL DISORDER; AGED; DISABILITY; DISEASE COURSE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; RISK;

ADULT; AGE FACTORS; AGED; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHENOTYPE; PROGNOSIS; RECURRENCE; RISK;

EID: 84921019317     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514528762     Document Type: Article

References (33)

1. Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol. 2008 ; 255: 280-287
2. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 ; 61: 1528-1532
3. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010 ; 133: 1914-1929
4. Kalincik T, Vaneckova M, Tyblova M, et al. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One. 2012 ; 7: e50101
5. Lhermitte F, Marteau R, Gazengel J, et al. The frequency of relapse in multiple sclerosis. A study based on 245 cases. Z Neurol. 1973 ; 205: 47-59
6. Mowry EM, Deen S, Malikova I, et al. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry. 2009 ; 80: 400-403
7. Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler J. 2006 ; 12: 769-774
8. Kalincik T, Spelman T, Trojano M, et al. Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis. PLoS One. 2013 ; 8: e63480
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 ; 50: 121-127
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983 ; 33: 1444-1452
11. Horakova D, Kalincik T, Dolezal O, et al. Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand. 2012 ; 126: 390-397
12. Deen S, Bacchetti P, High A, et al. Predictors of the location of multiple sclerosis relapse. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1190-1193
13. Greer J, Csurhes P, Muller D, et al. Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis. J Immunol. 2008 ; 180: 6402-6410
14. Gourraud P-A, Sdika M, Khankhanian P, et al. A genome-wide association study of brain lesion distribution in multiple sclerosis. Brain. 2013 ; 136: 1012-1024
15. Mowry EM, Carey RF, Blasco MR, et al. Association of multiple sclerosis susceptibility variants and early attack location in the CNS. PLoS One. 2013 ; 8: e75565
16. Bramow S, Frischer JM, Lassmann H, et al. Demyelination versus remyelination in progressive multiple sclerosis. Brain. 2010 ; 133: 2983-2998
17. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis. Pathology of recurrent lesions. Brain. 1993 ; 116: 681-693
18. Bennetto L, Burrow J, Sakai H, et al. The relationship between relapse, impairment and disability in multiple sclerosis. Mult Scler J. 2011 ; 17: 1218-1224
19. Cossburn M, Ingram G, Hirst C, et al. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler J. 2012 ; 18: 45-54
20. Fay AJ, Mowry EM, Strober J, et al. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler J. 2012 ; 18: 1008-1012
21. Kalincik T, Vivek V, Jokubaitis VG, et al. Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 2013 ; 136: 3609-3617
22. Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1368-1374
23. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 ; 83 (3). 282-7
24. Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology. 2009 ; 73: 1616-1623
25. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003 ; 126: 770-782
26. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 ; 133: 1900-1913
27. West T, Wyatt M, High A, et al. Are initial demyelinating event recovery and time to second event under differential control?. Neurology. 2006 ; 67: 809-813
28. Amato MP, Ponziani G, Bartolozzi ML, et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci. 1999 ; 168: 96-106
29. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 ; 116: 117-134
30. Mowry EM, Pesic M, Grimes B, et al. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology. 2009 ; 72: 602-608
31. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012 ; 380: 1819-1828
32. Lublin F, Cofield S, Cutter G, et al. Randomized study combining interferon & glatiramer acetate in multiple sclerosis. Ann Neurol. 2013 ; 73 (3). 327-40
33. Campbell Z, Sahm D, Donohue K, et al. Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis. Neurology. 2012 ; 78: 1493-1499